(VCYT) Veracyte - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92337F1075

Stock: Thyroid, Prostate, Bladder, Breast, Lung

Total Rating 28

Risk 31

Buy Signal -0.64

Diagnostics & Research » Biotechnology
Age: 12.3y

Market Cap: 3,010m
Avg Trading Vol: 32.1M USD

ATR: 5.24%
Peers RS (IBD): 20.00

EPS (Earnings per Share)

EPS CAGR: 18.42%
EPS Trend: 69.9%

Last SUE: -1.75
Qual. Beats: 0

Revenue

Rev. CAGR: 19.63%
Rev. Trend: 98.9%

Last SUE: 1.85
Qual. Beats: 3

Risk 5d forecast
Volatility	51.6%
Relative Tail Risk	-9.56%

Reward TTM
Sharpe Ratio	-0.12
Alpha	-37.83

Character TTM
Beta	1.195
Beta Downside	0.727

Drawdowns 3y
Max DD	50.09%
CAGR/Max DD	0.28

Description: VCYT Veracyte January 14, 2026

Veracyte, Inc. (NASDAQ: VCYT) is a molecular diagnostics company that commercializes genomic tests for multiple cancer types, including Afirma for thyroid nodules, Decipher for prostate and bladder cancers, Prosigna for breast cancer, and Percepta for lung cancer, while also developing the nCounter analysis platform. The firm, incorporated in 2006 and headquartered in South San Francisco, rebranded from Calderome in 2008.

Key recent metrics: Q4 2023 revenue rose 27% YoY to $84 million, driven by expanding Decipher adoption in the U.S. prostate market, which now represents roughly 35% of the test’s total volume. The company’s cash runway extends through mid-2025, with operating cash flow turning positive in the latest quarter after a 15% reduction in SG&A spend. A strategic partnership with Roche, announced in early 2024, grants Veracyte access to Roche’s global distribution network, potentially accelerating market penetration in Europe where genomic testing reimbursement is tightening but expected to grow at a 9% CAGR through 2028.

For a deeper, data-driven perspective on Veracyte’s valuation dynamics, you might explore the analytical tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income: 30.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.75 > 1.0
NWC/Revenue: 76.15% < 20% (prev 67.37%; Δ 8.79% < -1%)
CFO/TA 0.08 > 3% & CFO 108.2m > Net Income 30.3m
Net Debt (-275.1m) to EBITDA (47.1m): -5.84 < 3
Current Ratio: 6.23 > 1.5 & < 3
Outstanding Shares: last quarter (79.7m) vs 12m ago 1.56% < -2%
Gross Margin: 68.53% > 18% (prev 0.68%; Δ 6785 % > 0.5%)
Asset Turnover: 37.47% > 50% (prev 33.36%; Δ 4.11% > 0%)
Interest Coverage Ratio: 12.4k > 6 (EBITDA TTM 47.1m / Interest Expense TTM 2000 )

Altman Z'' -3.13

A: 0.28 (Total Current Assets 449.2m - Total Current Liabilities 72.2m) / Total Assets 1.37b
B: -0.31 (Retained Earnings -418.8m / Total Assets 1.37b)
C: 0.02 (EBIT TTM 24.7m / Avg Total Assets 1.32b)
D: -3.88 (Book Value of Equity -426.9m / Total Liabilities 110.1m)
Altman-Z'' Score: -3.13 = D

Beneish M -3.16

DSRI: 0.84 (Receivables 47.8m/48.8m, Revenue 495.1m/425.3m)
GMI: 0.99 (GM 68.53% / 67.76%)
AQI: 0.91 (AQ_t 0.63 / AQ_t-1 0.69)
SGI: 1.16 (Revenue 495.1m / 425.3m)
TATA: -0.06 (NI 30.3m - CFO 108.2m) / TA 1.37b)
Beneish M-Score: -3.16 (Cap -4..+1) = AA

What is the price of VCYT shares?

As of February 07, 2026, the stock is trading at USD 36.19 with a total of 1,203,480 shares traded.
Over the past week, the price has changed by -4.96%, over one month by -20.71%, over three months by -13.19% and over the past year by -16.80%.

Is VCYT a buy, sell or hold?

Veracyte has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy VCYT.

StrongBuy: 7
Buy: 2
Hold: 1
Sell: 0
StrongSell: 1

What are the forecasts/targets for the VCYT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	47.7	31.7%
Analysts Target Price	47.7	31.7%
ValueRay Target Price	35.3	-2.5%

VCYT Fundamental Data Overview February 03, 2026

P/E Trailing = 102.9189
P/E Forward = 27.027
P/S = 6.0795
P/B = 2.435
Revenue TTM = 495.1m USD
EBIT TTM = 24.7m USD
EBITDA TTM = 47.1m USD
Long Term Debt = 40.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.28m USD (from shortTermDebt, last quarter)
Debt = 40.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -275.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.68b USD (3.01b + Debt 40.5m - CCE 366.4m)
Interest Coverage Ratio = 12.4k (Ebit TTM 24.7m / Interest Expense TTM 2000 )
EV/FCF = 27.33x (Enterprise Value 2.68b / FCF TTM 98.2m)
FCF Yield = 3.66% (FCF TTM 98.2m / Enterprise Value 2.68b)
FCF Margin = 19.83% (FCF TTM 98.2m / Revenue TTM 495.1m)
Net Margin = 6.12% (Net Income TTM 30.3m / Revenue TTM 495.1m)
Gross Margin = 68.53% ((Revenue TTM 495.1m - Cost of Revenue TTM 155.8m) / Revenue TTM)
Gross Margin QoQ = 69.22% (prev 68.97%)
Tobins Q-Ratio = 1.96 (Enterprise Value 2.68b / Total Assets 1.37b)
Interest Expense / Debt = 0.00% (Interest Expense 2000 / Debt 40.5m)
Taxrate = 6.24% (1.61m / 25.7m)
NOPAT = 23.2m (EBIT 24.7m * (1 - 6.24%))
Current Ratio = 6.23 (Total Current Assets 449.2m / Total Current Liabilities 72.2m)
Debt / Equity = 0.03 (Debt 40.5m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = -5.84 (Net Debt -275.1m / EBITDA 47.1m)
Debt / FCF = -2.80 (Net Debt -275.1m / FCF TTM 98.2m)
Total Stockholder Equity = 1.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.29% (Net Income 30.3m / Total Assets 1.37b)
RoE = 2.50% (Net Income TTM 30.3m / Total Stockholder Equity 1.21b)
RoCE = 1.98% (EBIT 24.7m / Capital Employed (Equity 1.21b + L.T.Debt 40.5m))
RoIC = 1.91% (NOPAT 23.2m / Invested Capital 1.21b)
WACC = 10.18% (E(3.01b)/V(3.05b) * Re(10.32%) + D(40.5m)/V(3.05b) * Rd(0.00%) * (1-Tc(0.06)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.41%
[DCF Debug] Terminal Value 74.50% ; FCFF base≈81.5m ; Y1≈100.6m ; Y5≈171.3m
Fair Price DCF = 28.78 (EV 2.00b - Net Debt -275.1m = Equity 2.27b / Shares 79.0m; r=10.18% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 69.95 | EPS CAGR: 18.42% | SUE: -1.75 | # QB: 0
Revenue Correlation: 98.87 | Revenue CAGR: 19.63% | SUE: 1.85 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.32 | Chg30d=-0.020 | Revisions Net=-2 | Analysts=10
EPS next Year (2026-12-31): EPS=1.53 | Chg30d=-0.073 | Revisions Net=+6 | Growth EPS=-7.8% | Growth Revenue=+11.4%

Additional Sources for VCYT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle